CD19 and interstitial lung disease: The initial report of treatment of anti-synthetase syndrome with CD19-targeting CAR T cells involved a 41-year-old patient with persistent myositis and interstitial lung disease refractory to high-dose glucocorticoids and immunosuppressants, including rituximab and azathioprine [47].